Payment overview · 2025
General Payments
$779.63
25 reported records · 4 companies
Healthcare provider profile · identity verified
Cynthia Tam, DO
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1992871933
Verified facts
What the public records show
CMS Open Payments records show Cynthia Tam, DO received $779.63 in general payments during 2025 across 25 reported records.
Gilead Sciences, Inc. accounted for 47.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $371.86 | 47.7% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$188.89 | 24.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.31 | 23.8% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.57 | 4.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $779.63 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $188.89 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $133.79 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $51.52 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
113 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1694 | 484 |
| Amlodipine Besylate | Amlodipine Besylate | 1243 | 349 |
| Losartan Potassium | Losartan Potassium | 896 | 257 |
| Metoprolol Succinate | Metoprolol Succinate | 562 | 163 |
| Omeprazole | Omeprazole | 560 | 175 |
| Metformin Hcl | Metformin Hcl | 532 | 140 |
| Jardiance | Empagliflozin | 431 | 96 |
| Ammonium Lactate | Ammonium Lactate | 424 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 334 | 108 |
| Raloxifene Hcl | Raloxifene Hcl | 297 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 286 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 259 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 255 | 66 |
| Januvia | Sitagliptin Phosphate | 215 | 56 |
| Alendronate Sodium | Alendronate Sodium | 207 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 199 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 45 |
| Donepezil Hcl | Donepezil Hcl | 176 | 50 |
| Glipizide Er | Glipizide | 169 | 40 |
| Ketoconazole | Ketoconazole | 165 | 44 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 158 | 35 |
| Mometasone Furoate | Mometasone Furoate | 148 | 95 |
| Vascepa | Icosapent Ethyl | 134 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 131 | 49 |
| Farxiga | Dapagliflozin Propanediol | 128 | 33 |
| Simvastatin | Simvastatin | 125 | 39 |
| Famotidine | Famotidine | 124 | 33 |
| Montelukast Sodium | Montelukast Sodium | 121 | 33 |
| Atenolol | Atenolol | 114 | 32 |
| Azithromycin | Azithromycin | 113 | 94 |
| Vemlidy | Tenofovir Alafenamide | 113 | 13 |
| Azelastine Hcl | Azelastine Hcl | 108 | 40 |
| Finasteride | Finasteride | 105 | 36 |
| Celecoxib | Celecoxib | 103 | 43 |
| Lisinopril | Lisinopril | 101 | 29 |
| Gabapentin | Gabapentin | 100 | 29 |
| Meloxicam | Meloxicam | 92 | 46 |
| Meclizine Hcl | Meclizine Hcl | 87 | 53 |
| Allopurinol | Allopurinol | 86 | 24 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 84 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 65 |
| Ezetimibe | Ezetimibe | 72 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 32 |
| Ozempic | Semaglutide | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 70 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 27 |
| Clotrimazole | Clotrimazole | 67 | 27 |
| Furosemide | Furosemide | 67 | 25 |
| Mupirocin | Mupirocin | 65 | 46 |
| Eliquis | Apixaban | 62 | 17 |
| Tradjenta | Linagliptin | 61 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 18 |
| Incruse Ellipta | Umeclidinium Bromide | 58 | 13 |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 40 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 56 | 55 |
| Hydrocortisone | Hydrocortisone | 56 | 21 |
| Procto-Med Hc | Hydrocortisone | 56 | 20 |
| Xarelto | Rivaroxaban | 56 | 14 |
| Carvedilol | Carvedilol | 53 | 18 |
| Prolia | Denosumab | 53 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 14 |
| Folic Acid | Folic Acid | 48 | 15 |
| Diclofenac Epolamine | Diclofenac Epolamine | 45 | 31 |
| Livalo | Pitavastatin Calcium | 45 | suppressed |
| Acarbose | Acarbose | 42 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 15 |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | suppressed |
| Colchicine | Colchicine | 38 | 14 |
| Edarbi | Azilsartan Medoxomil | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 16 |
| Glimepiride | Glimepiride | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Prednisone | Prednisone | 34 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 31 | 23 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Entecavir | Entecavir | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Naproxen | Naproxen | 30 | 27 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Irbesartan | Irbesartan | 28 | 12 |
| Glipizide | Glipizide | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 21 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 19 |
| Ciclopirox | Ciclopirox Olamine | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 21 |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 21 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | 12 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 20 | 15 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | 12 |
| Valsartan | Valsartan | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $779.63 · 25 records | Gilead Sciences, Inc. | BREZTRI, FARXIGA, SYMPLICITY G3, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error